INNATE PHARMA
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases. The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.
INNATE PHARMA
Industry:
Biopharma Biotechnology Clinical Trials Medical Pharmaceutical
Founded:
1999-01-01
Address:
Marseille, Provence-Alpes-Cote D'Azur, France
Country:
France
Website Url:
http://www.innate-pharma.com
Total Employee:
51+
Status:
Active
Contact:
+33 (0)4 30 30 30 30
Email Addresses:
[email protected]
Total Funding:
201.1 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Google Analytics Google Tag Manager Google Universal Analytics Font Awesome Domain Not Resolving Global Site Tag
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
BNP Paribas
BNP Paribas investment in Post-IPO Debt - Innate Pharma
Societe Generale
Societe Generale investment in Post-IPO Debt - Innate Pharma
AstraZeneca
AstraZeneca investment in Corporate Round - Innate Pharma
QVT Financial
QVT Financial investment in Post-IPO Equity - Innate Pharma
Redmile Group
Redmile Group investment in Post-IPO Equity - Innate Pharma
Ardian
Ardian investment in Series C - Innate Pharma
Ace Capital Partners
Ace Capital Partners investment in Series C - Innate Pharma
NIF SMBC Ventures
NIF SMBC Ventures investment in Series C - Innate Pharma
Novo Nordisk
Novo Nordisk investment in Series C - Innate Pharma
Akka Venture
Akka Venture investment in Series C - Innate Pharma
Key Employee Changes
| Date | New article |
|---|---|
| 2020-07-16 | Innate Pharma announces the appointment of Joyson Karakunnel, MD, MSC, FACP as Chief Medical Officer |
Official Site Inspections
http://www.innate-pharma.com Semrush global rank: 1.64 M Semrush visits lastest month: 15.16 K
Unable to get host informations!!!
More informations about "Innate Pharma"
Innate Pharma - Crunchbase Company Profile
Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases. The …See details»
Company profile - Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate …See details»
Company profile | Innate Pharma
117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE +33 (0)4 30 30 30 30 Innate Pharma, Inc. 2273 Research Boulevard, Suite 350 Rockville, MD 20850, USASee details»
Leadership Team - Innate Pharma
117, Avenue de Luminy - BP 30191 13 009 Marseille FRANCE +33 (0)4 30 30 30 30 Innate Pharma, Inc. 2273 Research Boulevard, Suite 350 Rockville, MD 20850, USASee details»
Innate Pharma SA - Org Chart, Teams, Culture
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre …See details»
Investor Relations | Innate Pharma
Nov 19, 2024 At Innate Pharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are …See details»
Innate Pharma - LinkedIn
Innate Pharma | 25,485 followers on LinkedIn. Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for …See details»
Our history - Innate Pharma
Innate Pharma was founded in 1999 by a group of immunologists, four European Scientists - pioneers in the field of innate immunity (Alessandro Moretta, Marc Bonneville, Jean-Jacques …See details»
Innate Pharma Strengthens Leadership and Appoints Two …
Jan 4, 2024 Investors Innate Pharma Henry Wheeler Tel.: +33 (0)4 84 90 32 88 [email protected] Media Relations NewCap Arthur Rouillé Tel.: +33 (0)1 44 71 …See details»
Innate Pharma Appoints Jonathan Dickinson as …
Oct 14, 2024 Jonathan Dickinson joins Innate on November 1 and brings broad experience from leadership roles in biotech and big pharma. Current interim CEO and co-founder Hervé Brailly will support the transitionSee details»
COMPANY OVERVIEW - innate-pharma.com
(“AMF”),available on the AMF website (www.amf-france.org) or on the Company’s website (www.innate-pharma.com), and public filings and reports filed with the U.S. Securities and …See details»
Innate Pharma Appoints Jonathan Dickinson as New Chief …
Oct 13, 2024 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that its supervisory Board has appointed Jonathan Dickinson as …See details»
Welcome to Innate Pharma | Innate Pharma
Innate Pharma to participate in the Evercore ISI 4th Annual Healthconx Virtual Conference. November 24, 2021. Innate Pharma Third Quarter 2021 Report. November 16, 2021. Innate …See details»
Innate Pharma: Looking Like A Company We'll Regret …
5 days ago Innate Pharma (NASDAQ:IPHA)(OTCPK:IPHYF) is a biotech company focused on developing cancer medicines that rely on leveraging natural killer (NK) cells to drive a tumor …See details»
Innate Pharma reports Full Year 2023 financial results and …
Dec 31, 2023 Dr. Sonia Quaratino, MD, PhD, has been appointed as Executive Vice President and Chief Medical Officer of Innate Pharma, effective October 2023. On December 18, 2023, …See details»
Innate Pharma Reports First Half 2023 Financial Results …
Sep 14, 2023 Dr. Sonia Quaratino, MD, PhD, will join Innate Pharma as Executive Vice President and Chief Medical Officer, effective October 2023. Dr. Sonia Quaratino succeeds to …See details»
Innate Pharma reports Full Year 2021 financial results and …
Dec 31, 2021 In November 2021, Innate Pharma in collaboration with Sanofi, presented preclinical data from Innate’s proprietary, multi-specific NK cell engager platform, ANKET TM, …See details»
Innate Pharma announces exclusive license of antibodies …
Apr 3, 2023 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) today announced that it has entered into an exclusive license agreement with Takeda under which Innate grants …See details»